Mesenchymal Stem Cell Extracts for Epigenetic Cancer Reprogramming

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments lack effective compositions and methods for addressing proliferative diseases, particularly in reversing malignant cell phenotypes and preventing cancer progression.

Innovation Solution

Development of pharmaceutical compositions comprising intracellular and extracellular extracts from mesenchymal stem cells, which are formulated with a pharmaceutically acceptable carrier to treat proliferative diseases by modulating epigenetic modifications in cancer cells, thereby reprogramming them to a non-malignant state.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cancer treatments are used, then current standard therapy is provided, but effective compositions for reversing malignant cell phenotypes and preventing cancer progression are lacking

Engineering Contradiction:

Improveeffectiveness of cancer treatmentVSAvoidability to reverse malignant cell phenotypes

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts intracellular and extracellular components from mesenchymal stem cells to create pharmaceutical compositions. This extraction principle isolates the beneficial factors (growth factors, cytokines, structural elements, transcription factors) from the source cells, enabling their therapeutic application without using whole cells, thereby addressing the limitation of conventional treatments in reversing malignant phenotypes.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses mesenchymal stem cell extracts as an intermediary substance to mediate epigenetic modifications in cancer cells. These extracts contain biomolecules that act as intermediaries to induce reprogramming of malignant cells to a non-malignant state, providing a bridge between stem cell properties and cancer treatment without direct cell-to-cell contact.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If human embryonic stem cell extracts are used, then epigenetic reprogramming capability is achieved, but ethical and regulatory concerns arise

Engineering Contradiction:

Improveepigenetic reprogramming capabilityVSAvoidethical and regulatory concerns

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent inverts the traditional approach by using mesenchymal stem cells instead of embryonic stem cells to achieve epigenetic reprogramming. This inversion maintains the therapeutic benefit of epigenetic modification while avoiding the ethical and regulatory issues associated with embryonic stem cell usage, as mesenchymal stem cells are adult, differentiated cells with established clinical safety profiles.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent employs mesenchymal stem cells that can be obtained from adult sources (bone marrow, adipose tissue) rather than requiring embryonic sources. These cells are more readily available, ethically acceptable, and can be used to create therapeutic compositions without the regulatory hurdles associated with embryonic stem cells, effectively replacing problematic biological materials with acceptable alternatives.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentEP2533859B1Pharmaceutical compositions for the treatment and prevention of cancer

Publication Date: 2016.04.06 NAYACURE THERAPEUTICS

AI summary

The present invention concerns pharmaceutical compositions and methods for treating proliferative diseases, e.g. cancer using intracellular and extracellular extracts. These cell extracts can direct epigenetic reprogramming of the cancer cells and thereby reverse their neoplastic phenotype.